GI-1Homo sapiens (Human)Cancer cell line

Also known as: GI1

🤖 AI SummaryBased on 5 publications

Quick Overview

Human cell line for cancer research and drug development.

Detailed Summary

The GI-1 cell line is a human-derived cell line used in cancer research and drug development. It is characterized by its origin from a human tissue, though the specific tissue type and disease context are not specified in the available data. This cell line is part of a broader collection of cancer cell lines that are utilized for studying genetic and molecular mechanisms of cancer. The GI-1 cell line is part of the Cancer Cell Line Encyclopedia (CCLE) and is used in studies involving genomic profiling, drug sensitivity, and predictive modeling of anticancer drug responses. It is also involved in research on the identification of genetic predictors of drug sensitivity and the role of specific mutations in cancer progression. The cell line is used in studies that aim to understand the relationship between genetic alterations and therapeutic outcomes, contributing to the development of personalized cancer treatments.

Research Applications

Cancer researchDrug developmentGenomic profilingPredictive modeling of anticancer drug responsesIdentification of genetic predictors of drug sensitivity

Key Characteristics

Human-derivedPart of the Cancer Cell Line Encyclopedia (CCLE)Used in studies of genetic and molecular mechanisms of cancerUtilized for understanding the relationship between genetic alterations and therapeutic outcomes

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1231
Species	Homo sapiens (Human)
Tissue Source	Brain, left fronto-parietal lobe

Donor Information

Age	61
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Gliosarcoma
Lineage	CNS/Brain
Subtype	Gliosarcoma
OncoTree Code	GSARC

DepMap Information

Source Type	RIKEN
Source ID	ACH-000756_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Cys275Tyr (c.824G>A)	Unspecified	-	PubMed=8319216
MutationSimple	TERT	c.1-124C>T (c.228C>T) (C228T)	Unspecified	In promoter	from parent cell line Hep-G2
MutationSimple	RB1	p.Arg552Ter (c.1654C>T)	Homozygous	-	Unknown, Unknown
MutationSimple	CREBBP	p.Ser1680del (c.5036_5038CCT[1]) (c.5039_5041delCCT) (p.Ser1642del, c.4922_4924CCT[1])	Heterozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

D13S317

D16S539

9,10

D18S51

D19S433

13,14

D21S11

29,30

D2S1338

16,18

D3S1358

15,18

D5S818

D7S820

D8S1179

10,16

FGA

23,24

Penta D

11,12

Penta E

12,15

TH01

TPOX

8,12

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Establishment of a new cell line derived from a human gliosarcoma.";

Iwasaki K., Kikuchi H., Miyatake S.-i., Kondo S., Oda Y.

Neurosurgery 30:228-235(1992).

DOI PubMed

Brain tumors.";

Ali-Osman F.

(In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York; USA (1999).

DOI